Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14;35(39):2733-2779. doi: 10.1093/eurheartj/ehu284. Accessed 10 Jan 2018. PMID: 25173338
Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011 Dec 13;58(25):e212-260. doi: 10.1016/j.jacc.2011.06.011. Accessed 09 Jan 2018. PMID: 22075469
Maron MS. Hypertrophic cardiomyopathy: medical therapy. UpToDate. https://www.uptodate.com/. 01 Mar 2017. Accessed 10 Jan 2018.
Naidu SS. Diagnosis and management of hypertrophic cardiomyopathy. American College of Cardiology. http://www.acc.org/. 11 Feb 2015. Accessed 10 Jan 2018.
Semsarian C; Cardiovascular Genetics Working Group. Diagnosis and management of hypertrophic cardiomyopathy - position statement. Cardiac Society of Australia and New Zealand (CSANZ). http://www.csanz.edu.au/resources/#clinical-practice. 2016. Accessed 10 Jan 2018.
Sen-Chowdhry S, Jacoby D, Moon JC, et al. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol. 2016 Nov;13(11):651-675. doi: 10.1038/nrcardio.2016.140. Accessed 10 Jan 2018. PMID: 27681577
Maron MS. Hypertrophic cardiomyopathy: clinical manifestations, diagnosis, and evaluation. UpToDate. https://www.uptodate.com/. 04 Oct 2022. Accessed 03 Nov 2022.
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020 Jun;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064. PMID: 32466879
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 Dec;76(25):3022-3055. doi: 10.1016/j.jacc.2020.08.044. Accessed 03 Nov 2022. PMID: 33229115
Keam SJ. Mavacamten: first approval. Drugs. 2022 Jul;82(Suppl 10):1127-1135. doi: 10.1007/s40265-022-01739-7. Accessed 03 Nov 2022. PMID: 35802255
Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194. PMID: 37622657
Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 08 May 2024. doi: 10.1161/CIR.0000000000001250. PMID: 38718139
